SI0617019T1 - Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorophenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoate - Google Patents

Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorophenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoate

Info

Publication number
SI0617019T1
SI0617019T1 SI9430308T SI9430308T SI0617019T1 SI 0617019 T1 SI0617019 T1 SI 0617019T1 SI 9430308 T SI9430308 T SI 9430308T SI 9430308 T SI9430308 T SI 9430308T SI 0617019 T1 SI0617019 T1 SI 0617019T1
Authority
SI
Slovenia
Prior art keywords
enoate
hept
fluorophenyl
diisopropyl
dihydroxy
Prior art date
Application number
SI9430308T
Other languages
English (en)
Slovenian (sl)
Inventor
Rolf Dr. Angerbauer
Rolf Dr. Grosser
Werner Dr. Miles Incorporated Hinsken
Joachim Dr. Rehse
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SI0617019T1 publication Critical patent/SI0617019T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9430308T 1993-03-24 1994-03-11 Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorophenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoate SI0617019T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4309553A DE4309553A1 (de) 1993-03-24 1993-03-24 Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
EP94103776A EP0617019B1 (de) 1993-03-24 1994-03-11 Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-[4-(4-fluorphenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl]-3,5-dihydroxy-hept-6-enoat

Publications (1)

Publication Number Publication Date
SI0617019T1 true SI0617019T1 (en) 2000-08-31

Family

ID=6483717

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430308T SI0617019T1 (en) 1993-03-24 1994-03-11 Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorophenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoate

Country Status (10)

Country Link
US (1) US5502199A (da)
EP (1) EP0617019B1 (da)
JP (1) JPH06321900A (da)
AT (1) ATE193530T1 (da)
DE (2) DE4309553A1 (da)
DK (1) DK0617019T3 (da)
ES (1) ES2148252T3 (da)
GR (1) GR3034185T3 (da)
PT (1) PT617019E (da)
SI (1) SI0617019T1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19714343A1 (de) 1997-04-08 1998-10-15 Bayer Ag Chromatographische Enantiomerentrennung von Lactonen
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US6291574B1 (en) 1999-08-27 2001-09-18 General Electric Company Polyester molded articles
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
EP1345903A1 (en) * 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
DE10135013A1 (de) * 2001-07-18 2003-01-30 Bayer Ag Herstellung von Pyridylverbindungen
DE10216967A1 (de) * 2002-04-16 2003-11-13 Bayer Ag Verfahren zur Herstellung spezieller aromatischer Aldehyde
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
EP2161024A1 (de) 2008-09-05 2010-03-10 Universitätsklinikum Hamburg-Eppendorf Kombinationspräparat zur Behandlung von Krebs
CN104902892A (zh) 2012-02-02 2015-09-09 悉尼大学 泪液膜稳定性的改进
KR101363119B1 (ko) 2012-05-08 2014-02-13 한남대학교 산학협력단 활성화 비닐 에스테르를 이용한 비닐 단량체의 합성방법
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN104031034B (zh) * 2014-07-01 2017-01-04 上海信谊百路达药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2025168652A1 (en) 2024-02-05 2025-08-14 Astrazeneca Ab Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
TW202602866A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202602886A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
DE3905518A1 (de) * 1989-02-23 1990-10-11 Bayer Ag Substituierte phenoxyphenylpropionsaeure-derivate
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts

Also Published As

Publication number Publication date
DE4309553A1 (de) 1994-09-29
DE59409378D1 (de) 2000-07-06
JPH06321900A (ja) 1994-11-22
EP0617019B1 (de) 2000-05-31
ATE193530T1 (de) 2000-06-15
PT617019E (pt) 2000-11-30
ES2148252T3 (es) 2000-10-16
EP0617019A1 (de) 1994-09-28
DK0617019T3 (da) 2000-10-23
GR3034185T3 (en) 2000-11-30
US5502199A (en) 1996-03-26

Similar Documents

Publication Publication Date Title
SI0617019T1 (en) Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorophenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoate
EP1001036A3 (en) Enzymatic processes for resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
D'Oca et al. The addition of 2-tert-butyldimethylsilyloxyfuran to cyclic N-acyliminium ions containing cyclohexyl-based chiral auxiliaries
Viso et al. Kinetic resolution of racemic disubstituted 1-pyrrolines via asymmetric reduction with a chiral titanocene catalyst
MX9806209A (es) Proceso para la preparacion de d-treo-(r,r)-metil fenidato y recirculacion de enantiomeros no deseados a traves de epimerizacion.
HRP20031074A2 (en) Method for the preparation of escitalopram
Jacobi et al. Enantioselective syntheses of (+)-and (−)-Phaseolinic acid
ES2140778T3 (es) Procedimiento para la preparacion de compuestos de 2-cianoimidazol 1-sustituidos.
HU9202872D0 (en) Method for producing 2-aryl-3-substituted-5-(trifluoro-methyl)-pyrrhole derivatives of insecticidal, nematocidal and acaricidal effect
Ribbons et al. (+)-Muconolactone from arene biotransformation in Pseudomonas putida: Production, absolute configuration and enantiomeric purity.
Langer et al. Regio-and Diastereoselective Synthesis of 2-Alkylidenetetrahydrofurans by Domino SN/SN ‘and SN/SN Reactions of 1, 3-Dicarbonyl Dianions
Yamazaki et al. Novel lactonization of ethenetricarboxylate derivatives: Intermolecular trapping of alkenes
ATE288891T1 (de) Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
Futamura et al. Efficient route to (S)-azetidine-2-carboxylic acid
Endo et al. Photo-oxidation of L-tyrosine, an efficient 1, 4-chirality transfer reaction
Buisson et al. A chemoenzymatic preparation of both enantiomers of ω-hydroxymethyl-substituted lactones
CA2329210A1 (en) Process for preparation of enantiomerically pure n-methyl-n-[(1s)-1-phenyl-2((3s)-3-hydroxypyrrolidin-1-yl) ethyl]-2,2-diphenylacetamide
Chi-Nung et al. Enantioselective aldol reaction of chiral acyl thiazolidine thione derived boron enolates
EP0699902A4 (en) FILLER FOR HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AND METHOD FOR THE PRODUCTION THEREOF
Brózda et al. Transformation of (+)-thiomicamine into a new ligand for the enantioselective addition of methyllithium to prochiral imines
Lang et al. A stereoselective aldol reaction via diisopinocampheyl boron-enolate in preparation of chromane carboxylate with quaternary carbon
AU556793B2 (en) Sorbinil and methylsorbinil
Boyce et al. Naturally occurring 4-methylthiazolines. A total synthesis of (−)-[4R, 4S′]-didehydromirabazole A
HUT48230A (en) Process for producing hydroxyacetic acid derivatives and pharmaceutical compositions comprising such compounds